Kolexia
Wespiser Mylène Oncologie médicale
Wespiser Mylène
Oncologie médicale
Centre Léon-Bérard
Lyon, France
46 Activités
164 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Mélanome Tumeurs de l'oeil Carcinomes Néphrocarcinome Carcinome pulmonaire non à petites cellules Tumeurs de la tête et du cou Adénocarcinome à cellules claires Métastase tumorale

Collaborateurs

Voir plus
Klajer Elodie
Klajer Elodie
Hôpital Jean-Minjoz, Besançon, France
Bolognini Clément
Bolognini Clément
Hôpital Jean-Minjoz, Besançon, France
Goujon Morgan
Goujon Morgan
Hôpital Jean-Minjoz, Besançon, France
Herve Laure
Herve Laure
Hôpital Jean-Minjoz, Besançon, France

Industries

Voir plus
MSD
2 collaboration(s)
Dernière en 2022
Ipsen
1 collaboration(s)
Dernière en 2023
M3 Global Research Ltd
1 collaboration(s)
Dernière en 2023
Sandoz
1 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
LB1657 Tie-2 expressing monocytic myeloid-derived suppressor cells represent a resistance mechanism to anti-PD-1 therapy in melanoma
The Journal of investigative dermatology   01 septembre 2023
Uveal melanoma: In the era of new treatments.
Cancer treatment reviews   07 juillet 2023
Response to Chemoimmunotherapy Is Associated With Expansion of Systemic Antitumor CD4 + Th1 Response in Metastatic Non-Small Cell Lung Cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997)   20 février 2023
Chemotherapy to potentiate the radiation-induced immune response.
International review of cell and molecular biology   11 février 2023
203P Early remodeling of systemic antitumor T cell immunity in head and neck cancer patients treated by chemoradiation
Abstract Book of the ESMO Immuno-Oncology Congress 2022 7-9 December 2022   01 décembre 2022
210P Anti-CTLA-4 overcomes inhibitory effect of PD1high regulatory T cell on circulating antitumor CD4+ Th1 response in patients treated by anti-PD(L)-1
Abstract Book of the ESMO Immuno-Oncology Congress 2022 7-9 December 2022   01 décembre 2022
SO-20 Stanniocalcin 1 (STC1) in patients with refractory colorectal cancer (CRC) treated with regorafenib: An exploratory analysis of the CORRECT trial
Abstract Book of the ESMO 24th World Congress on Gastrointestinal Cancer 2022, Barcelona, Spain, 29 June -2 July 2022   01 juin 2022
8P STC1, a baseline predictive biomarker for overall survival in metastatic colorectal cancer (mCRC)
Molecular Analysis for Precision Oncology (MAP) Virtual Congress 2020   01 octobre 2020
Radiotherapy of oligometastases: Sequences and interactions with systemic therapies, example of kidney cancer.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   04 octobre 2019
Radiologic response assessment in metastatic colorectal cancers.
Bulletin du cancer   27 septembre 2019